Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4346

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg / 50 mcg strength, in a package containing 60 blisters. The label notes the product is for oral inhalation only, repackaged by RemedyRepack Inc., with storage instructions to keep in a dry place away from heat or sunlight. Manufacturer is Prasco Laboratories, Mason, OH.*

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure of fluticasone propionate shown as a detailed molecular diagram with labeled functional groups and atoms, including fluorine, oxygen, sulfur, carbon, and hydrogen.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure diagram showing the molecular arrangement of the active ingredients in Fluticasone Propionate and Salmeterol DISKUS, specifically depicting the fluticasone propionate and salmeterol compounds.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

A line graph showing the percent change in FEV1 over 12 weeks and endpoint for four groups: fluticasone propionate/salmeterol 100/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph includes markers and a table of subject numbers at various weeks for each group.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

A line graph showing the percentage change in FEV1 over 12 hours from baseline on Day 1 for four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The graph compares the effectiveness of these treatments in improving FEV1 over time.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

Line graph showing percentage change in FEV1 relative to Day 1 baseline over 12 hours. Four groups are compared: fluticasone propionate/salmeterol 100/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The vertical axis represents percentage change in FEV1, and the horizontal axis represents hours post-dose. The combined fluticasone/salmeterol group shows the highest increase.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph showing percentage change in FEV1 over 24 weeks for Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo groups. The graph plots week on the x-axis against % change in FEV1 on the y-axis, illustrating response differences between the three treatments over time.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line graph depicting percent change in FEV1 over time for three groups receiving fluticasone propionate/salmeterol 250/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The x-axis shows time from Day 1 through Week 24, and the y-axis shows percent change in FEV1. Data points indicate improvement in lung function, with sample sizes listed for each group at various intervals.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustration of a Fluticasone Propionate and Salmeterol DISKUS inhaler device showing labeled parts including the outer case, mouthpiece, lever, thumb grip, and counter. The center label indicates a strength of 100 mcg/50 mcg and that the powder is for respiratory inhalation.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. An arrow points to the right, indicating the action to slide or open the inhaler device for use.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional black and white illustration showing hands holding a DISKUS inhaler device. An arrow indicates the direction to slide the lever or mouthpiece, demonstrating how to prepare the inhaler for use.*

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

An instructional illustration showing a woman demonstrating the use of a DISKUS inhaler device, holding it near her mouth as if inhaling the powder medication. The image emphasizes proper inhaler positioning for respiratory administration.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

Black and white photograph showing a woman using a DISKUS inhaler device. She holds the inhaler close to her mouth, demonstrating the proper inhalation technique for administering the powdered respiratory medication.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

An instructional illustration showing hands holding and operating a Fluticasone Propionate and Salmeterol DISKUS inhaler. The image includes an arrow pointing to the left, indicating the direction to slide or open the device for use.*

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

Black-and-white illustration of a woman spitting liquid into a sink. There is a drinking glass with some liquid on the counter next to the sink. The image appears instructional, possibly related to oral care or hygiene practices.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder device containing 60 blisters of 100 mcg/50 mcg strength. The device is black with a circular white label on top indicating the dosage strength, product name, and spaces for pouch opened and use by dates. The device includes a dose indicator window showing the number 5.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.